Panascope operates as an independent brand with full ownership of its technology, quality systems, and customer relationships. Governance is not a bureaucratic overlay — it is the framework that ensures every strategic decision, from product architecture to market entry, serves one fixed reference point: patient safety.
Since its founding in 2007, Panascope has maintained a lean but rigorous governance structure. Shareholders appoint a Board of Directors responsible for strategic oversight. The Board brings together expertise in medical physics, radiology operations, regulatory affairs, and international business — ensuring that product decisions are grounded in clinical reality, not commercial convenience.
Specialized committees operate within the Board, proportionate to the company’s scale:
Audit Committee — Oversees financial reporting, internal controls, and external audits. Financial integrity matches image integrity.
Nomination Committee — Maintains the right balance of skills and independence on the Board, identifying candidates who understand diagnostic imaging.
Compensation Committee — Aligns executive rewards with long term value creation: system uptime, customer satisfaction, dose reduction.
The Board appoints executive officers to execute the strategic vision. Internal bodies support them: a Quality & Imaging Safety Committee (reviewing image quality complaints, radiation incidents, MRI safety events) and a Risk & Compliance Panel (regulatory changes, supplier audits, field corrections). An independent Internal Audit function reports directly to the Audit Committee.
Headquartered in Shenzhen, Panascope applies these governance principles consistently across all markets. Lean structure does not mean weak governance — it means every decision is visible, every risk is owned, every leader is accessible.
Governance is not a chart. It is a covenant with the people who rely on Panascope’s images: patients awaiting diagnosis, radiologists interpreting every pixel, technologists operating the equipment, hospital administrators managing finite resources.
Panascope is led by its founding team and an executive management group, with strategic direction reviewed by a Board of Directors. The Board’s primary function is to ensure that long term strategy — product portfolio, technology roadmaps, market expansion — remains aligned with core values and patient safety.
The Board delegates specific oversight to a Quality & Imaging Safety Committee, which reviews image quality complaints, radiation safety incidents, regulatory inspection findings, and MRI safety events (projectile risks, quench incidents). The committee meets quarterly and reports directly to the full Board. For a company of Panascope’s size and focus, this ensures that quality and safety never become subordinate to commercial pressure.
Three anchors guide every decision: transparency, accountability, and unwavering prioritization of patient safety. Design reviews, supplier selection, field correction decisions, and post market surveillance are all documented and auditable. Accountability extends to the radiologists and patients who depend on every image.
Panascope operates under a certified quality management system compliant with ISO 13485 — the same standard required of medical device manufacturers worldwide. The risk management process follows ISO 14971, with specific attention to imaging hazards: radiation dose, magnetic field safety, electrical safety (IEC 60601 series), and contrast media reactions.
NMPA registration in China, CE marking for select products (under MDR), and additional regional registrations are maintained directly by Panascope. Active surveillance of regulatory changes in China, the EU, and other target markets is continuous. Compliance is not a one time audit — it is daily discipline: document control, training, process adherence.
Because Panascope vertically integrates its technology and manufacturing resources, the company exercises direct control over supplier qualifications. A rigorous supplier qualification program includes annual on site audits, focusing on adherence to ISO 13485 and applicable imaging standards (IEC 60601 2 44 for CT, IEC 60601 2 33 for MRI). No component or assembly enters a Panascope system without passing internal verification.
We view radiologists, radiology technologists, hospital administrators, distributors, regulators, employees, and collaborative partners as essential stakeholders. Our engagement takes practical forms: user feedback sessions during beta testing and protocol development, post-installation surveys sent to every new site, open communication channels for distributors to report market intelligence and field issues, and regular quality and performance reviews with factory partners. We are not a distant, faceless entity. We are an accessible team, and we listen—because listening is the fastest route to meaningful improvement.
Subscribe to exclusive imaging insights & priority updates from Panascope. Elevate your practice with curated intelligence.
© Nortek HealthCare Group Ltd., 2009-2026. All rights reserved.
This site operates under the laws of the People's Republic of China. Your access and use constitute acceptance of these Terms of Use and our Privacy Policy. All content is governed by our Privacy Notice. For details or inquiries, please Contact Us or use the site's search function.
